Reduced Levels of 5-Alpha Reductase 2 in Adult Prostate Tissue and Implications for BPH Therapy

    February 2011 in “ ˜The œProstate/˜The œprostate ”
    Yinong Niu, Rongbin Ge, Libing Hu, Christian Diaz, Zongwei Wang, Chin‐Lee Wu, Aria F. Olumi
    TLDR Some men's prostate tissues have low enzyme levels due to genetic changes, possibly affecting treatment for prostate enlargement.
    The study investigated the expression of 5-α reductase 2 (5-AR 2) in benign prostatic hyperplasia (BPH) and its potential resistance to 5-AR 2 inhibitors. Using 42 human prostate tissue samples, the researchers found that 29% of benign prostate samples did not express the 5-AR 2 protein. They identified that the promoter region of 5-AR 2 contains a CpG island that is methylated in 39% of the samples, which strongly correlated with the absence of 5-AR 2 protein expression (P = 0.0025). The study concluded that methylation of the 5-AR 2 promoter might explain the low or absent expression of 5-AR 2 in some adult prostate tissues, potentially impacting the efficacy of BPH therapy.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    6 / 1000+ results

      community risks with finasteride and dutasteride

      in Research/Science  143 upvotes 3 weeks ago
      Finasteride and dutasteride have potential risks, including post-finasteride syndrome, but are commonly used for hair loss. RU58841, minoxidil, and needling are suggested as alternatives, though all treatments carry risks.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 11 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community Massive study on finasteride side effects released

      in Finasteride/Dutasteride  83 upvotes 2 years ago
      The release of a study on 5a-reductase inhibitors (finasteride and dutasteride) which showed an increased risk of depression, dementia, decreased libido, and reduced semen load as potential side effects; discussion around other forms of hair loss treatments such as topical minoxidil, RU58841, or opting to accept baldness; and advice to consider professional help for deeper issues related to hair loss.

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  42 upvotes 5 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

      community Hair Loss Drugs Ranked in Order of Efficacy

      in Research/Science  67 upvotes 1 year ago
      Dutasteride is likely the most effective treatment for male pattern baldness, followed by finasteride and minoxidil in various forms and dosages. Users discuss personal experiences, dosages, and potential side effects, with some considering combining treatments for better results.

    Similar Research

    5 / 1000+ results